INTERVENTION 1:	Intervention	0
Arm 1 (Nab-Paclitaxel + Bevacizumab - AC+PEG-G))	Intervention	1
Received intravenous (IV) administration of nabpaclitaxel 100 mg/m2 IV weekly for 12 weeks (nP x 12) with IV bevacizumab 10 mg/kg every 2 weeks (six doses), followed by IV doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 with pegfilgrastim 6 mg subcutaneously every 2 weeks for six cycles (ddAC x 6).	Intervention	2
x	LABO:0000148	54-55
x	LABO:0000148	95-96
x	LABO:0000148	147-148
x	LABO:0000148	174-175
x	LABO:0000148	283-284
x	LABO:0000148	298-299
doxorubicin	CHEBI:28748,BAO:0000639	172-183
cyclophosphamide	CHEBI:4026	197-213
INTERVENTION 2:	Intervention	3
Arm 2/3 (Nab-Paclitaxel/AC+PEG-G))	Intervention	4
Received nP x 12 followed by ddAC x 6, or received ddAC x 6 first followed by nP x 12, without bevacizumab	Intervention	5
x	LABO:0000148	12-13
x	LABO:0000148	34-35
x	LABO:0000148	56-57
x	LABO:0000148	81-82
DISEASE CHARACTERISTICS:	Eligibility	0
disease	DOID:4,OGMS:0000031	0-7
Histologically or pathologically confirmed breast cancer meeting one of the following criteria:	Eligibility	1
breast cancer	DOID:1612	43-56
Locally advanced disease (stage IIIB disease, stage IIB/IIIA, or stage IIIC disease)	Eligibility	2
disease	DOID:4,OGMS:0000031	17-24
disease	DOID:4,OGMS:0000031	37-44
disease	DOID:4,OGMS:0000031	76-83
Inflammatory disease meeting the following two clinicopathologic criteria:	Eligibility	3
disease	DOID:4,OGMS:0000031	13-20
Diffuse erythema AND edema (peau d'orange) of the breast involving the majority of the skin of the breast, i.e., more than 50%	Eligibility	4
diffuse	HP:0020034	0-7
erythema	HP:0010783	8-16
edema	HP:0000969	21-26
peau d'orange	HP:0025533	28-41
breast	UBERON:0000310	50-56
breast	UBERON:0000310	99-105
A biopsy demonstrating cancer either within the dermal lymphatics OR in the breast parenchyma itself	Eligibility	5
cancer	DOID:162	23-29
breast	UBERON:0000310	76-82
parenchyma	UBERON:0000353	83-93
HER2/neu-negative tumor as demonstrated by 0 or 1+ (weak or no staining) by DAKO, IHC, or equivalent test OR no gene amplification by FISH*	Eligibility	6
dako	BAO:0000889	76-80
gene	BAO:0000582	112-116
2+ by DAKO or IHC allowed provided FISH* negative	Eligibility	7
dako	BAO:0000889	6-10
NOTE: *A negative FISH test ratio is < 1.8 or FISH HER2 gene copy < 4.0; if only a positive or negative result is available from the FISH test, a negative result is acceptable for study entry	Eligibility	8
ratio	UO:0000190	28-33
gene	BAO:0000582	56-60
result	BAO:0000179	104-110
result	BAO:0000179	155-161
Hormone receptor status known	Eligibility	9
hormone	CHEBI:24621	0-7
receptor	BAO:0000281	8-16
PATIENT CHARACTERISTICS:	Eligibility	10
patient	HADO:0000008,OAE:0001817	0-7
Menopausal status not specified	Eligibility	11
Zubrod performance status 0-2	Eligibility	12
Granulocyte count > 1,500/mm^3	Eligibility	13
ANC  1,500/mm^3	Eligibility	14
Platelet count > 100,000/mm^3	Eligibility	15
platelet count	CMO:0000029	0-14
Hemoglobin 9.0 g/dL	Eligibility	16
hemoglobin	CHEBI:35143	0-10
Serum creatinine  1.5 times upper limit of normal (ULN)	Eligibility	17
creatinine	CHEBI:16737	6-16
Bilirubin  1.5 mg/dL	Eligibility	18
ALT and AST  3 times ULN	Eligibility	19
Alkaline phosphatase  2.5 ULN (unless bone metastasis is present in the absence of liver metastasis)	Eligibility	20
phosphatase	GO:0016791,BAO:0000295	9-20
present	PATO:0000467	57-64
liver	UBERON:0002107	83-88
Urine protein:creatinine ratio  0.5 OR urine protein < 1,000 mg on 24-hour urine collection	Eligibility	21
urine	UBERON:0001088	0-5
urine	UBERON:0001088	39-44
urine	UBERON:0001088	75-80
protein	CHEBI:36080,BAO:0000175	6-13
protein	CHEBI:36080,BAO:0000175	45-52
creatinine	CHEBI:16737	14-24
ratio	UO:0000190	25-30
Not pregnant or nursing	Eligibility	22
Negative pregnancy test	Eligibility	23
Fertile patients must use effective contraception	Eligibility	24
Able to take oral medications (e.g., no uncontrolled nausea, vomiting, or diarrhea, lack of physical integrity of the upper gastrointestinal tract, or malabsorption syndrome)	Eligibility	25
nausea	HP:0002018	53-59
vomiting	HP:0002013	61-69
diarrhea	HP:0002014,DOID:13250	74-82
malabsorption	HP:0002024	151-164
syndrome	DOID:225	165-173
QTc < 500 msec by EKG	Eligibility	26
LVEF normal by MUGA or ECHO (for patients with hypertension or for patients > 60 years of age)	Eligibility	27
hypertension	HP:0000822,DOID:10763	47-59
age	PATO:0000011	90-93
NYHA class II cardiac function by baseline ECHO/MUGA (for patients who have received central thoracic radiotherapy that included the heart in the radiotherapy port, or for patients who have a history of class II heart failure but are asymptomatic on treatment are eligible)	Eligibility	28
function	BAO:0003117,BFO:0000034	22-30
central	HP:0030645	85-92
radiotherapy	OAE:0000235	102-114
radiotherapy	OAE:0000235	146-158
heart	UBERON:0000948	133-138
heart	UBERON:0000948	212-217
history	BFO:0000182	192-199
No history of stroke (cerebrovascular accident), transient ischemic attack, or cardiac event within the past 12 months, including any of the following:	Eligibility	29
history	BFO:0000182	3-10
stroke	HP:0001297,DOID:6713	14-20
transient ischemic attack	HP:0002326,DOID:224	49-74
Myocardial infarction (including severe/unstable angina)	Eligibility	30
myocardial infarction	HP:0001658,DOID:5844	0-21
Coronary/peripheral artery bypass graft	Eligibility	31
artery	UBERON:0001637	20-26
Symptomatic congestive heart failure	Eligibility	32
congestive heart failure	HP:0001635,DOID:6000	12-36
Pulmonary embolism	Eligibility	33
pulmonary embolism	HP:0002204,DOID:9477	0-18
No poorly controlled hypertension, defined as recurrent or persistent ( 24 hours) elevated blood pressure (i.e., systolic blood pressure  140 mm Hg and/or diastolic blood pressure  90 mm Hg)	Eligibility	34
hypertension	HP:0000822,DOID:10763	21-33
recurrent	HP:0031796	46-55
blood	UBERON:0000178	91-96
blood	UBERON:0000178	122-127
blood	UBERON:0000178	165-170
systolic blood pressure	CMO:0000004	113-136
diastolic blood pressure	CMO:0000005	155-179
No other malignancy within the past 5 years except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer	Eligibility	35
skin cancer	DOID:4159	102-113
cervical cancer	DOID:4362	125-140
Peripheral neuropathy < grade 2	Eligibility	36
peripheral neuropathy	HP:0009830,DOID:870	0-21
PRIOR CONCURRENT THERAPY:	Eligibility	37
No prior tyrosine kinase inhibitors	Eligibility	38
tyrosine	CHEBI:18186	9-17
kinase	BAO:0000294	18-24
More than 5 years since prior chemotherapy, radiotherapy, or biologic therapy (e.g., trastuzumab or bevacizumab) for invasive breast cancer	Eligibility	39
radiotherapy	OAE:0000235	44-56
breast cancer	DOID:1612	126-139
At least 7 days since prior hormonal therapy	Eligibility	40
At least 7 days since prior and no concurrent strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconazole) or grapefruit juice	Eligibility	41
ketoconazole	CHEBI:47519,BAO:0000796	78-90
itraconazole	CHEBI:6076	92-104
clarithromycin	CHEBI:3732	106-120
atazanavir	CHEBI:37924	122-132
indinavir	CHEBI:44032	134-143
nefazodone	CHEBI:7494	145-155
nelfinavir	CHEBI:7496	157-167
ritonavir	CHEBI:45409	169-178
saquinavir	CHEBI:63621	180-190
telithromycin	CHEBI:29688	192-205
voriconazole	CHEBI:10023	207-219
No concurrent CYP3A4 inducers (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. John's wort)	Eligibility	42
dexamethasone	CHEBI:41879	37-50
phenytoin	CHEBI:8107	52-61
carbamazepine	CHEBI:3387	63-76
rifabutin	CHEBI:45367	88-97
phenobarbital	CHEBI:8069	111-124
No other concurrent therapy for the treatment of breast cancer except for bisphosphonates	Eligibility	43
breast cancer	DOID:1612	49-62
No concurrent brachytherapy	Eligibility	44
Outcome Measurement:	Results	0
Number of Patients With Pathological Complete Response Rate	Results	1
rate	BAO:0080019	55-59
Pathologic complete response (pCR), commonly defined as the absence of residual invasive cancer in both the breast and axillary lymph nodes, has emerged as a surrogate endpoint for disease-free and overall survival, as the achievement of a pCR is associated with a favorable long-term prognosis in all breast cancer subtypes.	Results	2
cancer	DOID:162	89-95
cancer	DOID:162	309-315
breast	UBERON:0000310	108-114
breast	UBERON:0000310	302-308
lymph	UBERON:0002391	128-133
breast cancer	DOID:1612	302-315
Time frame: pre-study pathology vs. post-chemo surgery pathology (approx. 39-42 weeks post-randomization)	Results	3
time	PATO:0000165	0-4
surgery	OAE:0000067	47-54
Results 1:	Results	4
Arm/Group Title: Arm 1 (Nab-Paclitaxel + Bevacizumab - AC+PEG-G))	Results	5
Arm/Group Description: Received intravenous (IV) administration of nabpaclitaxel 100 mg/m2 IV weekly for 12 weeks (nP x 12) with IV bevacizumab 10 mg/kg every 2 weeks (six doses), followed by IV doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 with pegfilgrastim 6 mg subcutaneously every 2 weeks for six cycles (ddAC x 6).	Results	6
x	LABO:0000148	77-78
x	LABO:0000148	118-119
x	LABO:0000148	170-171
x	LABO:0000148	197-198
x	LABO:0000148	306-307
x	LABO:0000148	321-322
doxorubicin	CHEBI:28748,BAO:0000639	195-206
cyclophosphamide	CHEBI:4026	220-236
Overall Number of Participants Analyzed: 98	Results	7
Measure Type: Count of Participants	Results	8
Unit of Measure: Participants  35  35.7%	Results	9
Results 2:	Results	10
Arm/Group Title: Arm 2/3 (Nab-Paclitaxel/AC+PEG-G))	Results	11
Arm/Group Description: Received nP x 12 followed by ddAC x 6, or received ddAC x 6 first followed by nP x 12, without bevacizumab	Results	12
x	LABO:0000148	35-36
x	LABO:0000148	57-58
x	LABO:0000148	79-80
x	LABO:0000148	104-105
Overall Number of Participants Analyzed: 113	Results	13
Measure Type: Count of Participants	Results	14
Unit of Measure: Participants  24  21.2%	Results	15
Adverse Events 1:	Adverse Events	0
Total: 22/96 (22.92%)	Adverse Events	1
Anemia  1/96 (1.04%)	Adverse Events	2
anemia	HP:0001903,DOID:2355	0-6
Febrile neutropenia  4/96 (4.17%)	Adverse Events	3
neutropenia	HP:0001875,DOID:1227	8-19
Heart failure  1/96 (1.04%)	Adverse Events	4
heart	UBERON:0000948	0-5
Abdominal pain  1/96 (1.04%)	Adverse Events	5
abdominal pain	HP:0002027	0-14
Dysphagia  1/96 (1.04%)	Adverse Events	6
dysphagia	HP:0002015	0-9
Mucositis oral  1/96 (1.04%)	Adverse Events	7
mucositis	DOID:0080178	0-9
Nausea  1/96 (1.04%)	Adverse Events	8
nausea	HP:0002018	0-6
Vomiting  2/96 (2.08%)	Adverse Events	9
vomiting	HP:0002013	0-8
Death NOS  0/96 (0.00%)	Adverse Events	10
death	OAE:0000632	0-5
Pain  1/96 (1.04%)	Adverse Events	11
pain	HP:0012531	0-4
Catheter related infection  1/96 (1.04%)	Adverse Events	12
Enterocolitis infectious  0/96 (0.00%)	Adverse Events	13
enterocolitis	HP:0004387	0-13
Adverse Events 2:	Adverse Events	14
Total: 3/60 (5.00%)	Adverse Events	15
Anemia  1/60 (1.67%)	Adverse Events	16
anemia	HP:0001903,DOID:2355	0-6
Febrile neutropenia  1/60 (1.67%)	Adverse Events	17
neutropenia	HP:0001875,DOID:1227	8-19
Heart failure  1/60 (1.67%)	Adverse Events	18
heart	UBERON:0000948	0-5
Abdominal pain  0/60 (0.00%)	Adverse Events	19
abdominal pain	HP:0002027	0-14
Dysphagia  0/60 (0.00%)	Adverse Events	20
dysphagia	HP:0002015	0-9
Mucositis oral  0/60 (0.00%)	Adverse Events	21
mucositis	DOID:0080178	0-9
Nausea  0/60 (0.00%)	Adverse Events	22
nausea	HP:0002018	0-6
Vomiting  0/60 (0.00%)	Adverse Events	23
vomiting	HP:0002013	0-8
Death NOS  1/60 (1.67%)	Adverse Events	24
death	OAE:0000632	0-5
Pain  0/60 (0.00%)	Adverse Events	25
pain	HP:0012531	0-4
Catheter related infection  0/60 (0.00%)	Adverse Events	26
Enterocolitis infectious  1/60 (1.67%)	Adverse Events	27
enterocolitis	HP:0004387	0-13
